BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study ...

- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related hospitalization) was met (Win Ratio of 1.8) with a highly statistically significant

Related Keywords

United States ,Ukraine ,American ,Vikram Bali ,American Heart Association ,Exchange Commission ,Bio Pharma Inc ,Nasdaq ,Drug Administration ,European Society Of Cardiology Congress ,Steering Committee ,Twitter ,Bridgebio Pharma Inc ,Linkedin ,Securities Exchange ,University Of South Carolina ,Win Ratio ,Hazard Ratio ,New Drug Application ,Bio Pharma ,Scientific Sessions ,European Society ,Cardiology Congress ,Daniel Judge ,Medical University ,South Carolina ,Bridgebio Pharma ,Securities Act ,Securities Exchange Act ,Exchange Act ,Risk Factors ,Annual Report ,Bio Media Contact ,Nation World ,Region ,